2-(5-Bromo-4-chloronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Catalog No. :
ACXERN631
CAS No. :
2621933-85-3
Molecular Formula :
C16H17BBrClO2
Molecular Weight :
367.48

IUPAC Name:2-(5-bromo-4-chloronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

2-(5-Bromo-4-chloronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(5-Bromo-4-chloronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
IUPAC Name2-(5-bromo-4-chloronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Molecular FormulaC16H17BBrClO2
Molecular Weight367.48
SMILESClC1=CC(B2OC(C)(C(C)(C)O2)C)=CC3=C1C(Br)=CC=C3
InChI KeyYJFAFDLIHSEQKO-UHFFFAOYSA-N
Synonym1,3,2-Dioxaborolane, 2-(5-bromo-4-chloro-2-naphthalenyl)-4,4,5,5-tetramethyl-;2-(5-Bromo-4-chloronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
CAS No.2621933-85-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACXERN631 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXERN631 route product structure diagram
    ACXERN6312621933-85-3
Inquiry

2. ACXERN631 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXERN631 route product structure diagram
    ACXERN6312621933-85-3
Inquiry

Comments (0)